INEOS Changed — Why I Rewrote Our Supplier Quality Agreement in 2024
A quality/brand compliance manager walks through why a supplier review framework from 2019 is a liability in 2025 — from unnoticed formulation changes in clay-filled polymers, to a frozen epoxy resin batch that taught me what 'industry standard' really means, to First Pharma-level traceability pressing upstream.
I review chemical lots for a living. Roughly 200 lot releases a year — maybe 180, I'd have to check the system — and in 2023 I rejected about 8% of first deliveries for spec deviation or incomplete documentation. That number sounds high. It isn't, in this industry.
So the argument below comes out of rejection logs, not a conference room.
By 2025, a company still signing quality agreements with INEOS as a "raw materials supplier" is absorbing risk it hasn't priced in.
That's not because INEOS got worse. If anything it's the opposite — the supplier evolved, and the paperwork on the buyer side didn't. What worked as a supplier review framework in 2019 is now a liability in 2025.
A vertically integrated supplier shifts where the problems hide
If you're familiar with INEOS as a chemical company, you probably know the vertical integration — base olefins and polymers on one end, resins and solvents further downstream. Good thing on paper: fewer middlemen, steadier pricing, steadier lead times.
What gets talked about less: vertical integration moves the origin of risk upstream.
Here's what I mean. When a supplier sells one thing, changes usually arrive from the outside — they send a price notice, maybe a product change notice. But when a company runs feedstock and finished product inside the same system, changes can happen quietly inside that system. By the time the material reaches you, the commercial documents look identical and the technical state has already shifted.
In 2022, on a line our team internally calls "Polymers Clay" — clay-filled polymer compounds for sealing applications — we got a batch where the spec sheet hadn't moved and the incoming inspection hadn't flagged anything. But our molding section ran a flow deviation three days straight. We traced it back: the resin base had come off a different internal line with a different formulation.
The vendor's response was that it was "within industry standard." Technically accurate. The problem was our agreement never required formulation-change notification. That batch cost us roughly $22,000 in scrap and rework — could be $24,000, I'm mixing it up with another project — plus three days of line downtime, which was the more annoying number.
The fix was unglamorous: we wrote "30 days written notice for critical formulation changes" into the contract, with change records submitted as an attachment. This didn't require a new process. ISO 9001:2015 clause 8.5.6 already says changes are controlled. Most buyers just never tied the supplier to it.
What "standard" means once epoxy resin freezes in transit
In my first year doing quality, I made a classic rookie mistake: I assumed "industrial standard" meant the same thing to every vendor.
Learned that the hard way on a batch of epoxy resin. Supplier quoted it as standard industrial grade. It shipped through a cold snap. When we opened the drums at the dock, viscosity was off and it poured with a grainy texture. Their reply: this is a physical phenomenon, within industry standard.
They weren't wrong. Can epoxy resin freeze? Yes — it can crystallize at low temperatures. It's not a defect, it's physics. But our purchase agreement never specified a storage and transport temperature window. So this wasn't their breach of contract. It was our omission of requirement.
After that I added two things to every contract: a defined transport and storage temperature range, and an open-drum inspection item for every lot arrival. I later carried the same logic over to INEOS's polymer feedstock — not because they'd had a comparable incident, but because the same risk exists anywhere material moves refrigerated, by sea, or across borders.
Trust is trust. Clauses are clauses. Those two things don't contradict each other.
First Pharma-level traceability is pressing upstream
One client of ours — a mid-size pharma outfit; their audit team internally goes by First Pharma — started changing their audit questions last year. It used to be "how do you trace the finished product." Now it's "which manufacturing site did every single upstream component come from."
That produces a very concrete change: the assumption of "one supplier, one quality agreement" no longer holds.
INEOS Olefins & Polymers USA spans multiple production sites. The same product line delivered from different sites can carry different batch records and deviation-handling workflows. Our old approach — one master agreement and done — became, this year, "one master agreement plus site-level annexes." The annexes spell out: site code, batch number format, deviation notification contact.
It's tedious work, honestly. But it solves a problem I've seen more than once: with the same supplier, site A reports problems proactively while site B digests them internally first. Not because anyone's dishonest — because process maturity differs by site. Plus, we only ever find out after the fact.
Let me head off the pushback
I know the objection: isn't this over-engineering the supplier relationship? Big companies hate this kind of precision-requesting behavior.
My answer is the reverse. This isn't added complexity — it's paying the complexity once, up front. Either you pay three extra pages at the contract stage, or you pay three extra weeks when a batch goes wrong. The first option is much cheaper.
If you've ever had a batch fail after weeks of planning, you know the feeling — the sinking one, before anyone has even calculated the cost.
I've wrestled with this too. In 2021, we were going back and forth between the established vendor and a newer one for two weeks. The established one quoted 12% higher and pushed back on terms; the newer one was cheaper and more flexible on paper. Every spreadsheet pointed to the new one. Something felt off — their replies were always half a beat slow.
We went with the established vendor and added the change-notification clause and site annexes. Later I heard the newer one had an unannounced formulation swap on another customer's line. I have no evidence that was systemic, but my read got confirmed.
Not saying everyone should copy that decision. Just that tighter clauses aren't a signal of distrust — they're putting trust somewhere it can be verified. Then again, I've only tested this on fairly complex supply chains. On simple, single-site purchases the older approach still works fine.
Bottom line
Back to the opening statement: INEOS in 2025 is no longer playing the role of a base-materials supplier only. Vertical capacity, multi-site delivery, downstream product reach — that's the normal result of an industry evolving, not a red flag.
But if your agreement still consists of "price, lead time, certificate of analysis," you're managing a 2025 supply chain with a 2019 tool. That gap doesn't get absorbed by the supplier. It gets absorbed by you.
Bottom line: when the supplier evolves, the clauses have to evolve with it. Because the most expensive thing in a chemical purchase is rarely the feedstock — it's the rework.
Materials context
Kuraray newsroom articles often connect polymer performance with commercial qualification needs. For a deeper review of a grade family, contact the relevant technical team and include application requirements, processing conditions, regional markets, and documentation expectations.